SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R)

| From

Previous Research has shown SelenoExcell(R) Supplementation to reduce Lung, Colon and Prostate Cancers by as much as 63%

FRESNO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) -- Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results - that were announced yesterday - used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See Related Website at .

The results of the SELECT TRIAL are consistent with previous animal studies. For example, Dr. David McCormick at the Experimental Toxicology and Carcinogenesis Division, IIT Research Institute in Chicago found no effects with selenomethionine supplementation on the prevention of prostate cancer in rats (Eur Urol 1999;35:464-467).

Such negative findings have not been observed for other forms of selenium. For example, research at Purdue University found SelenoExcell(R) High-Selenium Yeast to be more effective than selenomethionine in the reducing DNA damage in canine prostate cells (Waters et al, J. Natl Cancer Inst (2003); 95:237-240). Researchers at the University of Arizona and Cornell University reported in the Journal of American Medical Association (Clark et al, JAMA, Dec. 25, 1996-vol. 276, No.24).) that regular use of 200 micrograms per day of selenium in the form of SelenoExcell(R) reduced the incidences of lung, colon, and prostate cancers by 50-63%. Researchers at the Penn State University Cancer Institute found that supplementation with SelenoExcell(R), reduced serum PSA levels, a risk indicator for prostate cancer (El-Bayoumy et al, Cancer Epidemiology Vol. 11, 1459-1465, Nov., 2002). References to these and other studies can be found at the website, - under the research matrix "Cancer" section of the home page.

Paul A. Willis, CEO & President of Cypress Systems, Inc. stated that "Clearly we believe that the SELECT TRIAL should have included the standardized high-selenium yeast, which has been found effective in reducing cancer risk in animal studies and human clinical trials." High-selenium yeast is different from selenomethionine. It contains several different forms of organically-bound selenium in addition to selenomethionine.

According to Dr. Mark Whitacre, Cypress Systems' COO, "We suspect that the advantage of SelenoExcell(R) High-Selenium Yeast lies in its content of multiple forms of selenium, including some that are more direct acting in anti-carcinogenesis."

All trademarks are property of their respective owners.

News Source:
Like, Share, Save this press release:
  TWEET   SHARE   G+   STUMBLE   LinkedIn   Instapaper   Buffer

The content of the above press release was provided by the “news source” (Cypress Systems, Inc.) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2008 Cypress Systems, Inc. with newswire version Copr. © 2008 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Oct 21 2016:
[ count retired 8.4.16 ]

Drugs and Pharmaceuticals, or: Search

back to top
REFERENCES: Cypress Systems SelenoExcell, high-selenium yeast, Cypress Systems, Inc., SELECT TRIAL results, high-selenium yeast, SelenoExcell, more effective than selenomethionine in the reducing DNA damage in canine prostate cells, human clinical trials, CEO Paul A. Willis, Dr. Mark Whitacre, Experimental Toxicology and Carcinogenesis Division, IIT Research Institute, news, press release from Cypress Systems, Inc., Oct 29, 2008, Drugs and Pharmaceuticals, , , , , SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R)